Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung

NCT00503295 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT00503295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00503295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung
Lead sponsor
Oncolytics Biotech
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
April 30, 2011
Enrollment
53 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma family tumors, fibrosarcoma, leiomyosarcoma, malignant fibrous histiocytoma, osteosarcoma, sarcoma, synovial